Objective. Uterine myomas represent the most common benign gynecological tumors and about 40-60% of patients with fibroids are asymptomatic. The diagnosis is often incidental and the treatment depends on patient's age, size of fibroids, estimated rate of growth, woman's fertility plans and risk of malignancy. Despite the prevalence, scientific research regarding asymptomatic fibroids is still underfunded compared with other nonmalignant diseases and actually, no guidelines are reported about management and treatment of themselves. Material and method We conducted a review of literature from February to May 2017. PubMed (MEDLINE), Web of Science databases, EMBASE, Cochrane Library and Scopus database were systematically searched for records reporting on asymptomatic fibroids. Results. Further large studies are needed to define the management of asymptomatic fibroids, real indications to treatment and risks and benefits of a waiting strategy when no treatment is needed can be drawn. Conclusion. No standard guidelines for the management of asymptomatic fibroids have been reported. Treatment is individualized and depends on patient s age, size of fibroids, woman s fertility plans and risk of malignancy.
Uterine asymptomatic myomas: An overview from diagnosis to treatment / Di Donato, V.; Musella, A.; Bracchi, C.; Lecce, F.; Colagiovanni, V.; Di Pinto, A.; Santangelo, G.; Giannini, A.; Tomao, F.; Palaia, I.; Perniola, G.; Muzii, L.; Benedetti Panici, P.. - In: GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA. - ISSN 0391-9013. - 41:2(2019), pp. 76-83.
Uterine asymptomatic myomas: An overview from diagnosis to treatment
Di Donato V.;Musella A.;Bracchi C.;Colagiovanni V.;Santangelo G.;Tomao F.;Palaia I.;Perniola G.;Benedetti Panici P.
2019
Abstract
Objective. Uterine myomas represent the most common benign gynecological tumors and about 40-60% of patients with fibroids are asymptomatic. The diagnosis is often incidental and the treatment depends on patient's age, size of fibroids, estimated rate of growth, woman's fertility plans and risk of malignancy. Despite the prevalence, scientific research regarding asymptomatic fibroids is still underfunded compared with other nonmalignant diseases and actually, no guidelines are reported about management and treatment of themselves. Material and method We conducted a review of literature from February to May 2017. PubMed (MEDLINE), Web of Science databases, EMBASE, Cochrane Library and Scopus database were systematically searched for records reporting on asymptomatic fibroids. Results. Further large studies are needed to define the management of asymptomatic fibroids, real indications to treatment and risks and benefits of a waiting strategy when no treatment is needed can be drawn. Conclusion. No standard guidelines for the management of asymptomatic fibroids have been reported. Treatment is individualized and depends on patient s age, size of fibroids, woman s fertility plans and risk of malignancy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
